Exelixis price target raised to $38 from $34 at RBC Capital
RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...
Pharmaceutical Technology9d
Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer.
Zacks.com on MSN2mon
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
Investing15d
Exelixis downgraded, price target raised to $40 on CRC drug outlook
The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...
Business Insider15d
Exelixis downgraded to Market Perform from Outperform at BMO Capital
The firm has raised its target on zanzalintinib’s probability of success in CRC, which it now pegs at 50%, but views the success of the trial as “a toss-up” given the history of cabometyx ...